Page 8 - Cor Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CinCor Pharma is uncovering a great potential for combatting treatment-resistant and uncontrolled hypertension.

Brokerages expect CinCor Pharma, Inc. (NASDAQ:CINC – Get Rating) to report ($0.50) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for CinCor Pharma’s earnings. The highest EPS estimate is ($0.43) and the lowest is ($0.55). The company is expected to report its next quarterly earnings report […]

We have used the quarterly return data of companies that went public in Q1 2022 to rank the ten best performing IPOs in Q1 2022.

Brokerages expect CinCor Pharma, Inc. (NASDAQ:CINC – Get Rating) to announce earnings per share of ($0.50) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for CinCor Pharma’s earnings, with the highest EPS estimate coming in at ($0.44) and the lowest estimate coming in at ($0.59). The business is scheduled to […]

CinCor Pharma (NASDAQ:CINC – Get Rating) posted its earnings results on Tuesday. The company reported ($15.71) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.56) by ($14.15), MarketWatch Earnings reports. NASDAQ CINC traded up $0.09 on Thursday, hitting $15.39. 344 shares of the company traded hands, compared to its average volume of 247,779. […]